Incyte Corp. is expecting clinical data later this quarter from a second pivotal study, TRuE-AD1, of its topical formulation of JAK inhibitor, ruxolitinib, in mild-to-moderate atopic dermatitis, and the company says it is committed to developing ruxolitinib cream as a first-line option for the condition.
Atopic Dermatitis: Ruxolitinib And Baricitinib Spearheading New Therapies
Wave Of New Treatments Expected Over The Next Few Years.
Top-line Phase III results from Incyte’s TruE-AD2 study of ruxolitinib cream and Eli Lilly’s BREEZE-AD4 and BREEZE-AD5 studies of oral baricitinib show that the compounds achieved primary endpoints in atopic dermatitis, and they may eventually challenge Sanofi’s Dupixent’s growth in the sector.
More from Dermatological
• By
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
• By
Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.
• By
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.
• By
Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.
More from Therapy Areas
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.